114 related articles for article (PubMed ID: 9120683)
1. Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans.
Williamson PM; Kelly JJ; Whitworth JA
J Hypertens Suppl; 1996 Dec; 14(5):S37-41. PubMed ID: 9120683
[TBL] [Abstract][Full Text] [Related]
2. Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension.
Klanke B; Cordasic N; Hartner A; Schmieder RE; Veelken R; Hilgers KF
Nephrol Dial Transplant; 2008 Nov; 23(11):3456-63. PubMed ID: 18515791
[TBL] [Abstract][Full Text] [Related]
3. Metabolic and blood pressure responses to hydrocortisone in the syndrome of apparent mineralocorticoid excess.
Oberfield SE; Levine LS; Carey RM; Greig F; Ulick S; New MI
J Clin Endocrinol Metab; 1983 Feb; 56(2):332-9. PubMed ID: 6296185
[TBL] [Abstract][Full Text] [Related]
4. [Syndrome of apparent mineralocorticoid excess caused by a deficiency of 11 beta-hydroxysteroid dehydrogenase: clinical and genetic study in a Chilean family followed for 19 years].
Rodríguez JA
Rev Med Chil; 2000 Jan; 128(1):17-26. PubMed ID: 10883518
[TBL] [Abstract][Full Text] [Related]
5. Adrenocorticotrophin-induced hypertension: effects of mineralocorticoid and glucocorticoid receptor antagonism.
Li M; Wen C; Fraser T; Whitworth JA
J Hypertens; 1999 Mar; 17(3):419-26. PubMed ID: 10100081
[TBL] [Abstract][Full Text] [Related]
6. Are we missing a mineralocorticoid in teleost fish? Effects of cortisol, deoxycorticosterone and aldosterone on osmoregulation, gill Na+,K+ -ATPase activity and isoform mRNA levels in Atlantic salmon.
McCormick SD; Regish A; O'Dea MF; Shrimpton JM
Gen Comp Endocrinol; 2008 May; 157(1):35-40. PubMed ID: 18462736
[TBL] [Abstract][Full Text] [Related]
7. Ganglion blockade does not prevent cortisol-induced hypertension in man.
Williamson PM; Tam SH; Kelly JJ; Whitworth JA
Clin Exp Pharmacol Physiol; 2005 Apr; 32(4):294-6. PubMed ID: 15810994
[TBL] [Abstract][Full Text] [Related]
8. Spironolactone in essential hypertension: evidence against its effect through mineralocorticoid antagonism.
Hoffbrand BI; Edmonds CJ; Smith T
Br Med J; 1976 Mar; 1(6011):682-4. PubMed ID: 766908
[TBL] [Abstract][Full Text] [Related]
9. Apparent mineralocorticoid excess causing hypertension and hypokalemia in children.
New MI; Stoner E; DiMartino-Nardi J
Clin Exp Hypertens A; 1986; 8(4-5):751-72. PubMed ID: 3463439
[TBL] [Abstract][Full Text] [Related]
10. Acid-base and endocrine effects of aldosterone and angiotensin II inhibition in metabolic acidosis in human patients.
Henger A; Tutt P; Riesen WF; Hulter HN; Krapf R
J Lab Clin Med; 2000 Nov; 136(5):379-89. PubMed ID: 11079465
[TBL] [Abstract][Full Text] [Related]
11. Role of angiotensin II in the pressor response to cortisol in fetal sheep during late gestation.
Forhead AJ; Fowden AL
Exp Physiol; 2004 May; 89(3):323-9. PubMed ID: 15123568
[TBL] [Abstract][Full Text] [Related]
12. Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor.
Whitworth JA; Kelly JJ
J Endocrinol Invest; 1995; 18(7):586-91. PubMed ID: 9221279
[No Abstract] [Full Text] [Related]
13. Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor.
Montrella-Waybill M; Clore JN; Schoolwerth AC; Watlington CO
J Clin Endocrinol Metab; 1991 May; 72(5):1060-6. PubMed ID: 1850752
[TBL] [Abstract][Full Text] [Related]
14. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
15. Studies on spirolactone steroid antagonists in ACTH-induced hypertension in sheep.
Reid AF; Coghlan JP; Spence CD; Whitworth JA; Scoggins BA
J Steroid Biochem; 1989 Dec; 33(6):1213-21. PubMed ID: 2559253
[TBL] [Abstract][Full Text] [Related]
16. Adrenocorticotropin and cortisol-induced changes in urinary sodium and potassium excretion in man: effects of spironolactone and RU486.
Clore JN; Estep H; Ross-Clunis H; Watlington CO
J Clin Endocrinol Metab; 1988 Oct; 67(4):824-31. PubMed ID: 2843562
[TBL] [Abstract][Full Text] [Related]
17. Urinary free cortisol is not a biochemical marker of hypertension.
Krall P; Carvajal C; Ortiz E; Muñoz C; Garrido JL; Mosso L; Fardella C
Am J Hypertens; 2007 Apr; 20(4):459-65. PubMed ID: 17386356
[TBL] [Abstract][Full Text] [Related]
18. Decreased threshold for the nitric oxide donor glyceryl trinitrate in cortisol-induced hypertension in humans.
Kelly JJ; Tam SH; Williamson PM; Whitworth JA
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1317-8. PubMed ID: 17973874
[TBL] [Abstract][Full Text] [Related]
19. [Brain mineralocorticoid receptor and blood pressure control in the conscious normotensive rat].
Rahmouni K; Barthelmebs M; Imbs JL; De Jong W
Arch Mal Coeur Vaiss; 1998 Aug; 91(8):1009-12. PubMed ID: 9749155
[TBL] [Abstract][Full Text] [Related]
20. Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of spironolactone and losartan regarding long-term blood pressure and target organ damage.
Baumann M; Hermans JJ; Janssen BJ; Peutz-Kootstra C; Witzke O; Heemann U; Smits JF; Boudier HA
J Hypertens; 2007 Dec; 25(12):2504-11. PubMed ID: 17984673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
